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Abstract
RA is a syndrome consisting of different pathogenetic subsets in which distinct molecular mechanisms
may drive common final pathways. Recent work has provided proof of principle that biomarkers may be
identified predictive of the response to targeted therapy. Based on new insights, an initial treatment
algorithm is presented that may be used to guide treatment decisions in patients who have failed one
TNF inhibitor. Key questions in this algorithm relate to the question whether the patient is a primary vs a
secondary non-responder to TNF blockade and whether the patient is RF and/or anti-citrullinated peptide
antibody positive. This preliminary algorithm may contribute to more cost-effective treatment of RA, and
provides the basis for more extensive algorithms when additional data become available.
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RA is a syndrome rather than a disease
entity
RA is a chronic inflammatory disease affecting synovial
tissue in multiple joints. The diagnosis is based on signs
and symptoms, like the number of affected joints, the pat-
tern of joint involvement as well as the presence of ele-
vated levels of acute-phase reactants, autoantibodies and
erosions on radiographs. Interestingly, patients with iden-
tical clinical signs and symptoms may have very dissimilar
patterns of leucocyte infiltration [1, 2] and cytokine
expression [3, 4] in their synovium. In addition to marked
heterogeneity between RA patients with regard to synovial
leucocyte infiltration and activation of genes associated
with inflammation [5, 6], there is also evidence of vari-
ability in genes associated with stromal cells such as
fibroblast-like synoviocytes [7, 8].
There is not only inter-individual heterogeneity with re-
spect to the gene signature in the synovial tissue, but also
in the peripheral blood. For instance, elevated expression
levels of IFN type I regulated genes, consistent with the
activation of a pathogen-response programme, have been
observed in the peripheral blood of about half of the RA
patients [9, 10]. The notion that RA should be viewed as a
syndrome consisting of more than one pathogenetic entity
is strongly supported by the differences between patients
with detectable anti-citrullinated peptide antibodies
(ACPA) and those who are ACPA negative. ACPA-positive
disease is associated with unfavourable outcome [11, 12],
and there is an association between ACPA positivity
and the presence of the specific genotype encoding
the shared epitope [13], smoking [14, 15] and periodon-
titis [14]. It appears likely that the ACPA-negative RA
group may be further subdivided into different groups
based on molecular mechanisms underlying the disease
process.
Finally, the variable clinical response to targeted thera-
pies, including TNF blockade [1618] and treatment with
rituximab [19], abatacept [20] and tocilizumab [21],
strongly highlights the variability of RA. The typical re-
sponse to any targeted therapy in RA patients who have
failed MTX is shown in Fig. 1. Of note, such ACR re-
sponses may be seen on the group level for any of the
above-mentioned targeted therapies, but patients who fail
one targeted drug are not necessarily the same failing
a different mechanism of action. Collectively, the data
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cesses may lead to common final pathways and shared
clinical signs and symptoms associated with the syn-
drome termed RA. If we want to improve the effectiveness
of current treatment, it will be critical to first understand
the reasons as to why patients respond or not respond to
a given treatment. The next step may be to select sub-
groups of patients who are more likely to exhibit a favour-
able response to a specific mechanism of action.
Effective anti-rheumatic treatments
affect common final pathways
The importance of collecting data on the primary site of
inflammation, the synovium, to understand the effects of
anti-rheumatic treatment is illustrated by the observation
that clinical arthritis activity is accompanied by persistent
histologic signs of synovitis after treatment with huma-
nized anti-cluster of differentiation 52 (CD52) antibodies
or chimeric anti-CD4 antibodies, despite profound deple-
tion of peripheral blood lymphocytes [22, 23]. Similarly, it
has for instance been shown that B-lineage cells may per-
sist in the synovium in some RA patients after treatment
with rituximab, in spite of marked depletion of peripheral
blood B cells in nearly all patients [24, 25].
Successful treatment with DMARDs, such as gold [26],
MTX [2729], LEF [29] and CSs [3032], has consistently
been associated with decreased mononuclear cell infiltra-
tion in the synovium. Similarly, successful treatment of RA
patients withinfliximab [3338],anakinra[39]andrituximab
[24, 25, 4042] results in reduced synovial inflammation.
In one study, patients were randomly assigned to treat-
ment with prednisolone according to the
Combinatietherapie Bij Reumatoide Artritis (COBRA) regi-
men or placebo for 2 weeks [32]. This study identified
synovial sublining macrophages as the best biomarker
associated with the clinical response to CSs. Next, the
utility of macrophages in the synovial sublining as a can-
didate biomarker was tested across discrete interventions
and kinetics [43, 44]. The consistent relationship between
the decrease in synovial macrophages and clinical im-
provement after anti-rheumatic treatment was also con-
firmed by other studies [4548]. Taken together, these
studies indicate that successful treatment of RA results
in decreased accumulation of synovial macrophages
associated with clinical improvement, independent of
the specific mechanism of action (Fig. 2).
Understanding resistance to
anti-rheumatic biologic treatment
The development of biologic agents that selectively block
the effects of pro-inflammatory cytokines, interfere with
co-stimulatory signals, or deplete immune cells has pro-
vided a major advance in the treatment of RA. However,
not all patients respond to a given treatment, and there-
fore there is a clear need for the identification of clinical,
radiological and molecular biomarkers that can help us
understand the variable response to targeted therapy.
There are as yet no known predictive biomarkers of re-
sponse to abatacept and tocilizumab; hence, I will focus
on biomarkers measured at baseline that might be pre-
dictive of response to anti-TNF or rituximab treatment.
The primary response to anti-TNF treatment
Blockade of TNF using systemic administration of soluble
receptors or mAbs (all parenterally administered protein
therapeutics or biologicals) has improved the treatment
of RA considerably. These anti-TNF therapies have
shown clinical efficacy in 6070% of the RA patients
with persistent disease activity in spite of conventional
FIG.1ACR responses typically observed 24 weeks after initiation of treatment with any of the biologics used for the
treatment of patients with RA who have failed MTX. Although the results on the group level may be comparable, individual
patients who fail one mechanism of action are not necessarily the same as those failing a different mechanism of action.
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well as other approved biologics, do not only improve
clinical signs and symptoms of arthritis activity, but in
most patients there is also protection against progression
of joint destruction, reduced disability and a beneficial
effect in terms of quality of life. To date, three TNF-
targeting agents have dominated the biologic manage-
ment of RA: adalimumab, a fully human mAb; etanercept,
a soluble receptor construct; and infliximab, a chimeric
mAb. Two other TNF antagonists, certolizumab and goli-
mumab, have more recently also been shown to be ef-
fective in RA.
In spite of the improvement observed in most patients
after anti-TNF treatment, some patients do not respond.
So far no factors have been identified that fully explain
or predict the heterogeneous primary response, as deter-
mined 1216 weeks after initiation of treatment. However,
a small pilot study suggested that pre-treatment TNF level
in the synovium might be related to clinical efficacy, where
TNF-blocking therapy could be most effective in patients
with high pre-treatment TNF levels [35]. Next, a study of
143 RA patients demonstrated increased TNF expression
levels in the intimal lining layer and synovial sublining of
patients responding at Week 16 compared with non-
responding to infliximab treatment [49]. In line with these
findings, there was increased infiltration by macrophages,
including CD163
+ resident tissue macrophages and mye-
loid-related protein 8
+ (MRP8
+) and MRP14
+ infiltrating
macrophages, as well as T cells in responders compared
with non-responders; these cells are the main source of
TNF in the synovium of patients with RA. Consistent with
the clinical experience that the response to TNF blockade
is not a dichotomous phenomenon [50], there was no dis-
tinct threshold value in TNF expression in the synovium of
patients with RA. Multivariate logistic regression analysis
of synovial markers showed that TNF expression in the
synovial sublining at baseline could explain 10% of the
variance in response to therapy [49]. After adjusting for
disease activity at baseline this further increased to
17%. Hence, the predictive value of synovial TNF expres-
sion is statistically significant, but overall limited. In other
words, this study provided proof of principle confirming
that biomarkers predictive of the response to anti-TNF
therapy might be identified, but there is no role for meas-
urement of synovial TNF levels in isolation in the context of
personalized health care. In line with these findings, an-
other study demonstrated that the primary response to
anti-TNF treatment is related to higher TNF bioactivity in
the peripheral blood [51].
A subsequent study revealed a highly significant rela-
tionship between the presence of synovial lymphocyte ag-
gregates at baseline in the synovium and the primary
clinical response to infliximab treatment defined at 16
weeks [52]. When the presence of synovial lymphocyte
aggregates was added into a combined prediction
model with synovial TNF expression, the 28-joint DAS
(DAS-28) at baseline, and the presence of ACPA, the pres-
ence of lymphocyte aggregates increased the prediction
of response from 19 to 29%.The positive predictive value
of the model was 85% and the negative predictive value
was 53% [52]. Other studies using gene array analysis of
synovial tissue samples aimed at the identification of bio-
markers predictive of response to anti-TNF treatment
have generally suggested that patients with a more inflam-
matory gene profile are more likely to respond to TNF
blockade [53, 54], although results have been somewhat
variable [55]. These studies have also shown that it is piv-
otal to account for the microarchitecture and infiltrating
cell populations when studying gene expression patterns
in rheumatoid synovial tissue [54].
FIG.2Clinical signs and symptoms of RA are associated with macrophage infiltration and activation. Different patho-
genetic mechanisms may drive this common final pathway. Successful treatment of RA results in decreased accumu-
lation of synovial macrophages associated with clinical improvement, independent of the specific mechanism of action.
Mø: macrophage; FLS: fibroblast-like synoviocyte.
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monocytes from RA patients identified CD11c as a bio-
marker that was capable of distinguishing at baseline be-
tween patients who would be responders to adalimumab
treatment and those who would be non-responders [56].
CD11c levels significantly correlated with the ACR
response. However, CD11c was not predictive of the
response to adalimumab treatment in patients who used
concomitant MTX therapy, limiting its use as biomarkers
predictive of the response to anti-TNF treatment, as this is
mostly used in combination [56].
Several studies have investigated the relationship be-
tween the presence of RFs and ACPA on the one hand
and the primary response to anti-TNF treatment on the
other, with conflicting results [5760]. Together, it appears
unlikely that autoantibody status can be used to predict
the response to anti-TNF treatment in individualized health
care. Other work has focused on different factors ranging
from, for example, genetic factors [61, 62] to body
weight [61] as predictive biomarkers of response. Many
of these studies deepen our insight into the mechanisms
involved in the primary response to anti-TNF therapy.
Although proof of principle has been obtained that pre-
dictive biomarkers can be identified, none of these has at
present sufficient positive predictive value and in particu-
lar negative predictive value to be used for treatment
decisions at baseline in the individual patient. For future
research, the combination of multiple markers bears most
promise to improve the performance of a biomarker-
guided approach, as it could reduce the extensive overlap
in individual marker levels that exists between responders
and non-responders.
Having shown that on the group level, primary
non-responders to a first TNF antagonist have less TNF-
and less inflammation-dependent disease, the clinical
question arises whether the primary non-responders are
less likely to respond to a second TNF inhibitor after
having failed a first one compared with RA patients who
are anti-TNF naı ¨ve. Twenty-eight uncontrolled studies
observed clinical improvement after switching to adalimu-
mab, etanercept or infliximab in patients who had discon-
tinued at least one previous TNF inhibitor [63]. A limitation
is that most studies do not distinguish between the pri-
mary response (primary non-response could be defined
as lack of clinical improvement determined 1216 weeks
after initiation of treatment) and secondary response (sec-
ondary non-response here defined as initial clinical im-
provement followed by loss of response usually at least
6 months after initiation of treatment), which appears very
relevant as the mechanisms for failure may be completely
different. In addition, patients who discontinued anti-TNF
therapy because of adverse events are often also grouped
among the TNF inadequate responders. On the group
level, clinical response to a second TNF inhibitor is
lower than the response in anti-TNF-naı ¨ve patients
[6466]. Clinical response to a second TNF inhibitor is,
however, not decreased in patients who switched be-
cause of secondary non-response associated with the de-
velopment of anti-drug antibodies (see below) [65, 67].
Importantly, patients who failed adalimumab treatment
without anti-drug antibodies had a diminished response
after switching to etanercept treatment compared with
patients who were TNF naı ¨ve [67]. These data are consist-
ent with other studies, showing that the clinical response
to a second or third TNF antagonist is decreased in
primary non-responders to a first TNF inhibitor [68, 69].
Taken together, primary non-responders to anti-TNF
treatment have less TNF-dependent disease and are
less likely to respond to a second TNF inhibitor.
Therefore, one might preferably prescribe a biologic with
a different mechanism of action in primary non-
responders to a first TNF blocker.
The secondary response to anti-TNF treatment
In an environment where biologics with different mechan-
isms of action are available, many RA patients treated with
TNF inhibitors discontinue their treatment over time due to
lack of efficacy, adverse events as well as other reasons
[70]; after 5 years, the cumulative drug survival is 50%.
Loss of response may be explained in part by the devel-
opment of anti-drug antibodies. Antibodies against inflix-
imab were detected in 22 (43%) RA patients during the
first year after initiation of treatment with 3mg/kg inflixi-
mab every 8 weeks, although 86% were receiving
concomitant MTX [71]. Patients without detectable anti-
infliximab antibodies were significantly more often
classified as responders compared with patients with
detectable anti-infliximab antibodies after 1 year [71].
The development of anti-drug antibodies is not limited to
chimeric antibodies. In another cohort study, anti-
adalimumab antibodies were detected in 21 (17%) pa-
tients during 28 weeks of adalimumab treatment; 79%
used concomitant MTX [71]. Clinical non-responders at
Week 28 had anti-adalimumab antibodies significantly
more often than good responders [71]. After 3 years, the
development of anti-adalimumab antibodies was asso-
ciated with lower drug concentrations and lower likelihood
of low disease activity or remission [72]. Thus, one of the
mechanisms underlying secondary non-response to
anti-TNF treatment is completely unrelated to the mo-
lecular mechanisms promoting synovial inflammation.
Therefore, one could postulate that secondary
non-responders may still respond to treatment with a
second TNF inhibitor, at least when non-response is ex-
plained by the presence of anti-drug antibodies. Clinical
improvement after treatment with a second TNF inhibitor
is indeed apparently not diminished in patients who
switched because of secondary non-response associated
with the development of anti-drug antibodies [65, 67].
Thus, one could consider trying a second TNF antagonist
in patients who initially responded to a first TNF inhibitor,
but who lost response over time.
The response to rituximab treatment
As the clinical response to rituximab treatment can be
variable, we studied the relationship between changes in
synovial cell populations during the first 16 weeks after
rituximab treatment and the clinical response determined
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vium could significantly predict clinical response to treat-
ment, although there was perhaps a minor trend towards
more B cells at baseline in responders compared with
non-responders. Importantly, linear regression analysis
identified a statistically significant, positive correlation be-
tween the change in intimal macrophages and plasma
cells between 4 and 16 weeks on the one hand and the
decrease in disease activity after 24 weeks on the
other [41]. The decrease in plasma cells between 4 and
16 weeks was predictive for the decrease in DAS-28. The
change in plasma cell numbers was also correlated with a
decrease in the serum levels of ACPA. Consistent with
these results, the change in plasma cells differed signifi-
cantly between responders and non-responders [41].
Other studies have confirmed the importance of the (indir-
ect) effect of rituximab treatment in RA on B-lineage cells
associated with autoantibody production for the ultimate
clinical effectiveness [73, 74]. The notion that clinical im-
provement after rituximab treatment can only be achieved
if numbers of autoantibody-producing plasma cells after
treatment are low is supported by the association be-
tween a high number of CD20-negative pre-plasma cells
before treatment with rituximab, incomplete B-lineage cell
depletion and worse clinical response [74]. Other bio-
markers of response recently identified include the pres-
ence of a Type I IFN signature in peripheral blood
mononuclear cells at baseline that was negatively corre-
lated with the response to rituximab [75]. Among various
effects, Type I IFNs may stimulate the production of a
proliferation-induced ligand (APRIL) and B-lymphocyte
stimulator (BLyS) and directly enhance B-cell survival.
Although B cells may have different roles, including anti-
gen presentation, stimulation of T cells and cytokine pro-
duction, the studies discussed above suggest that in
particular the role of autoantibodies produced by plasma
cells may be important in RA [76]. Consistent with this
hypothesis, RA patients who test positive for RFs and/or
ACPA are more likely to respond to rituximab treatment
than autoantibody-negative patients [7779]. Therefore,
the recommendation is to preferably prescribe a biologic
other than rituximab in RA patients who are both RF and
ACPA negative. If an RF and ACPA-double-negative pa-
tient has failed all other mechanisms of action, rituximab
could still be tried in light of the possibility that the patient
may have autoantibodies other than those detected by the
currently used tests for RF and ACPA.
A next question is whether a patient should receive a
second course of rituximab treatment if there was no clin-
ical response to a first course of rituximab treatment. As
discussed above, in autoantibody-positive RA patients,
lack of response may be related to persistence of
B-lineage cells. Conceivably, more intense dosing regi-
mens might result in clinical improvement in these pa-
tients. Although results have been somewhat variable, it
appears unlikely that re-treatment of non-responders to a
first rituximab course with the currently approved dosing
regimens will result in robust clinical improvement
[74, 80, 81]. Of particular interest is a randomized
placebo-controlled trial showing that patients who did
not achieve a clinical response to the first course were
no more likely to achieve response to a second course
(n=126) than to placebo (n=60) [81]. In light of the avail-
ability of other therapeutic options, for individual patients
who are rituximab non-responders, other treatment op-
tions should be considered [82].
A preliminary treatment algorithm
In RA patients who have failed conventional therapy with
DMARDs, biologic treatment may be indicated. At pre-
sent, in most cases, anti-TNF therapy will be employed,
consistent with the recommendations of the European
League Against Rheumatism (EULAR) [83]. It should
be noted, however, that tocilizumab and abatacept have
also been approved for the treatment of MTX-inadequate
responders. Depending on the features of the indi-
vidual patient, one may consider the prescription of a
biologic with a mechanism of action other than TNF block-
ade. In any case, the objective at any time is to
achieve remission, or at least a state of low disease ac-
tivity [83].
If a TNF inhibitor is initiated and there is subsequent
lack of clinical response, one could consider a second
TNF inhibitor [84], rituximab [19], tocilizumab [20] or aba-
tacept [20]. First, it should be noted that a decision may
be influenced by patient-specific characteristics such as
the presence of systemic manifestations like anaemia,
comorbidity, the need to prescribe biologic treatment
without concomitant treatment with conventional
DMARDs, or the risk of specific infections like tubercu-
losis. Secondly, there are at present no published data
on reliable biomarkers predictive of the response to toci-
lizumab or abatacept. Thus, at present these biologics
can be considered in all TNF-inadequate responders.
Apart from these considerations, the first question that
should be asked is: is the patient a primary non-responder
or a secondary non-responder to the first TNF antagonist
(see above)? If the patient is a primary non-responder, the
patient is more likely to have less TNF-dependent disease
and a lower likelihood of robust clinical improvement to a
second TNF antagonist (Fig. 3). If the patient exhibited
initial clinical improvement, but lost response over time
(secondary non-responder), then a second TNF inhibitor
may be considered, as the lack of response may be
related to the development of anti-drug antibodies rather
than TNF-independent disease.
The next question to ask is if the patient is RF positive
and/or ACPA positive. If both RF and ACPA are negative,
the likelihood of clinical improvement after rituximab treat-
ment is diminished and biologics other than rituximab
should be considered (Fig. 3).
If an RA patient has been treated with rituximab, but
there was no clinical response to the first course, then
the likelihood of a good response to a second course ac-
cording to the current dosing schedule appears low. Thus,
biologic treatment other than rituximab should be initiated
(Fig. 3).
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As RA is a syndrome comprising different pathogenetic
subsets, some patients may be more likely to respond
to a specific therapeutic intervention than others. Recent
work has provided proof of principle that biomarkers may
be identified predictive of the response to targeted ther-
apy. Most of these biomarkers increase the insight into the
mechanisms promoting synovial inflammation and joint
destruction as well as in the mechanism of action of the
treatment. However, the use of biomarkers in the context
of individualized health care is still limited. In addition to
the need for identification of novel biomarkers, combin-
ation of multiple markers bears most promise to improve
the performance of a biomarker-guided approach.
Based on recent insights, an initial algorithm can be
made assisting in treatment decisions in patients who
have failed one TNF inhibitor. Key questions in this algo-
rithm relate to the question whether the patient is a pri-
mary vs a secondary non-responder to TNF blockade and
whether the patient is autoantibody positive.
This preliminary algorithm may contribute to more
cost-effective treatment of RA, and supports the rationale
for the development of more extensive algorithms. For this
purpose more data are needed, most importantly, the
identification of biomarkers predictive of the response to
tocilizumab and abatacept. Therefore, there is a need for
well-designed clinical studies aimed at the identification of
disease subgroups that would benefit from one mechan-
ism of action over another. Future research should also
focus on the reasons for secondary loss of response and
the potential value of therapeutic drug monitoring.
Together, these approaches may improve the ACR re-
sponses compared with those shown in Fig. 1. Finally,
there is a need for the identification of biomarkers predict-
ive of adverse events.
Rheumatology key messages
. RA is a syndrome rather than one disease entity.
. Effective anti-rheumatic treatments affect common
final pathways.
. A therapeutic algorithm can be made for patients
who have failed one TNF inhibitor.
Disclosure statement: P.P.T. has served as a consultant
to Abbot, Amgen, AstraZeneca, BMS, Genentech, MSD,
Novartis, Pfizer, and Roche.
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